| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Miller Robert E | Chief Financial Officer | Buy | 750 | $7.02 | $5,267.50 | +3.1% | |
| Mar 9, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Pernock David | Pres. &Chief Comm. Officer | Buy | 450 | $77.84 | $35,028.49 | New | |
| Mar 8, 2017 | EBS Emergent Biosolutions Inc. | Hauer Jerome M | Director | Sell | 2,576 | $31.27 | $80,558.48 | -13.9% | |
| Mar 8, 2017 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 6,500 | $8.43 | $54,762.50 | -2.7% | |
| Mar 8, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Miller Robert E | Chief Financial Officer | Buy | 1,000 | $6.93 | $6,930.00 | +7.3% | |
| Mar 7, 2017 | ALKS Alkermes Plc. | Frates James M83 | SVP, Alks Inc; CFO Alks | Sell | 25,000 | $59.08 | $1,477,068.08 | -9.5% | |
| Mar 6, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 12,000 | $27.45 | $329,400.00 | -100% | |
| Mar 6, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Umscheid Marc | Chief Strategy/ Mkt Officer | Buy | 750 | $6.82 | $5,115.00 | New | |
| Mar 6, 2017 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,250 | $7.90 | $25,675.00 | -2.7% | |
| Mar 3, 2017 | SNOA Sonoma Pharmaceuticals, Inc. | Schutz James J | Chief Executive Officer | Buy | 800 | $6.78 | $5,420.88 | +3.5% | |
| Mar 3, 2017 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 3,200 | $17.19 | $55,008.00 | -12.3% | |
| Mar 3, 2017 | JNJ Johnson & Johnson | Duato Joaquin | Exec VP, Ww Chair, Pharma | Sell | 50,000 | $123.62 | $6,181,140.00 | -42.2% | |
| Mar 2, 2017 | ALKS Alkermes Plc. | Breyer Robert A | Director | Sell | 4,000 | $60.00 | $240,000.00 | -35.9% | |
| Mar 2, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 20,000 | $60.00 | $1,200,000.00 | -22.4% | |
| Mar 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $57.06 | $85,590.00 | -15.8% | |
| Mar 1, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 84,615 | $20.96 | $1,773,163.85 | -0.6% | |
| Feb 28, 2017 | JNJ Johnson & Johnson | Kapusta Ronald A | Controller, CAO | Sell | 14,543 | $122.26 | $1,777,954.46 | -32.7% | |
| Feb 28, 2017 | JNJ Johnson & Johnson | Pruden Gary J | Exec VP, Ww Chair, Med Devices | Sell | 16,299 | $122.21 | $1,991,943.17 | -27.2% | |
| Feb 27, 2017 | PAHC Phibro Animal Health Corp | Welch Daniel A | Sr VP, Human Resources | Sell | 5,000 | $28.30 | $141,500.00 | -100% | |
| Feb 27, 2017 | PAHC Phibro Animal Health Corp | Carlson Gerald K | Director | Sell | 12,000 | $28.29 | $339,480.00 | -100% | |
| Feb 27, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 225,000 | $83.06 | $18,688,950.00 | -0.2% | |
| Feb 24, 2017 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | Chief Accounting Officer | Sell | 2,962 | $16.53 | $48,961.86 | -9.9% | |
| Feb 24, 2017 | ANIK Anika Therapeutics, Inc. | Ahn Edward S. | Chief Tech &Strategy Officer | Sell | 640 | $49.47 | $31,660.80 | -8.1% | |
| Feb 22, 2017 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Chief Scientific Officer | Sell | 1,800 | $16.94 | $30,492.00 | -7.8% | |
| Feb 22, 2017 | ANIK Anika Therapeutics, Inc. | Cheung Sylvia | Chief Financial Officer | Sell | 4,000 | $49.02 | $196,095.79 | -3.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.